# mRNA-1010 (mFlusiva)

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/mrna-1010-mflusiva
Canonical HTML page: https://getbiobrief.com/entity/mrna-1010-mflusiva

## Timeline

- **2026-08-05**: FDA Approval of mRNA-1010 — The FDA approved Moderna's mRNA flu vaccine for adults 50+, with traditional approval for ages 50–64 and accelerated approval for ages 65+.

## Recent coverage (1 stories)

### Moderna's mRNA-1010 Approved with 27.4% Efficacy Lead in 65+ Population
2026-08-06 21:00:31 · Sentiment: Strongly positive · Impact: 8/10 · Sources: 2

Moderna's mRNA flu vaccine mRNA-1010 secures FDA approval, showing a 27.4% relative efficacy advantage over standard-dose in adults 65+, validating mRNA technology for seasonal influenza.
Full story: https://getbiobrief.com/story/moderna-mrna-1010-fda-approval-27-4-percent-efficacy

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.